2023 World Conference on Lung Cancer (Posters)-EP11.03. Real-World Efficacy of Atezolizumab in Patients with Previously Treated Advanced NSCLC in Spain - TRACKER Study

EP11.03. Real-World Efficacy of Atezolizumab in Patients with Previously Treated Advanced NSCLC in Spain - TRACKER Study - PDF(Abstract)

Back to course

Pdf Summary

This study, known as the TRACKER study, aimed to assess the real-world efficacy of atezolizumab in patients with previously treated advanced non-small cell lung cancer (NSCLC) in Spain. Atezolizumab is an immunotherapy drug that has been shown to improve overall survival in NSCLC patients in clinical trials. However, data specific to Spain's patient population is lacking.<br /><br />The study reviewed the medical records of 455 patients with advanced/metastatic NSCLC who were treated with atezolizumab monotherapy between March 2018 and September 2019 in 27 hospitals across Spain. The primary endpoint was overall survival, and secondary endpoints included overall response rates, duration of response, treatment-related adverse events, and progression-free survival.<br /><br />The results showed that the median overall survival was 9.08 months, with overall survival rates at 6 and 12 months of 62.2% and 38.8%, respectively. The median progression-free survival was 3.38 months, with progression-free survival rates at 6 and 12 months of 33.8% and 19.6%, respectively. The overall response rate was 7.1%, and the median duration of response was 7.1 months.<br /><br />Adverse events occurred in 24.8% of patients, with the most frequent being asthenia, pruritus, and rash. The study concluded that patients enrolled in the TRACKER study had worse baseline characteristics compared to those in previous clinical trials. However, the overall survival outcomes in key subgroups were consistent with the results from previous trials, supporting the real-world efficacy of atezolizumab in previously treated advanced NSCLC patients in Spain.<br /><br />This study provides important real-world data on the effectiveness and safety of atezolizumab in NSCLC patients in Spain, reinforcing its potential as a treatment option in this setting.

Asset Subtitle

Enric Carcereny

Meta Tag

Speaker Enric Carcereny

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

TRACKER study

atezolizumab

non-small cell lung cancer

NSCLC

immunotherapy drug

Spain

overall survival

response rates

adverse events

progression-free survival